Q-omics provides the consensus-scored TMEM139 profile across patient tissues and cancer cell-line models. TMEM139 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM139 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, TMEM139 RNA expression shows 17,105 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, KICH, and KIRP as cancer lineages where TMEM139 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM139 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM139 survival associations across molecular data types. TMEM139 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM139 RNA expression–survival associations across cancer types. High TMEM139 expression shows unfavorable associations in PAAD and COAD, but favorable associations in HNSC, KIRC, THCA and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM139 RNA expression.
This table summarizes TMEM139 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM139. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM139 shows lower tumor expression in KICH, LUAD, THCA, LUSC and BRCA and higher tumor expression in STAD. The KICH box plot shows higher TMEM139 RNA expression in normal versus tumor tissue (log2 FC = −3.343, t-test p < 0.001).
This table shows molecular features associated with TMEM139 in patient tissues and cancer cell lines. In patient samples, TMEM139 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM139 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
